Neuronax

Neuronax is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Neuronax. NEURONAX is a privately-held biotech company focusing on the development of candidate-drugs for the treatment of traumatic or severe degenerative disorders of the central nervous system (CNS). NEURONAX focuses particular nervous disorders for which the capacities to treat patients are limited and the "unmet needs"​ are very important. Among them, injuries of the CNS are among the major clinical problems since the consequences are currently irreversible resulting in serious disabilities in sensory and motor function. Our most advanced product candidate, NX210, a neuro-protective and neuro-regenerative peptide, was deduced from a naturally secreted protein produced early during emryonic development by specialized ependymal cells located in the brain. This promising first-in-class candidate has been shown to improve recovery and neurological function and may adress treatment of various acute and chronic disorders, including but not limited to spinal cord injuries (SCI), traumatic brain injuries (TBI), stroke, Alzheimer or Parkinson’s diseases. For more information, please visit our website.